Raltegravir Potassium Patent Expiration

Raltegravir Potassium is Used for treating HIV infection by inhibiting integrase. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc in its drug Isentress on Oct 12, 2007. Another drug containing Raltegravir Potassium is Isentress Hd.


Raltegravir Potassium Patents

Given below is the list of patents protecting Raltegravir Potassium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Isentress Hd US10772888 Solid pharmaceutical compositions containing an integrase inhibitor Mar 30, 2032 Msd Sub Merck
Isentress Hd US9649311

(Pediatric)

Solid pharmaceutical compositions containing an integrase inhibitor Apr 21, 2031 Msd Sub Merck
Isentress Hd US9649311 Solid pharmaceutical compositions containing an integrase inhibitor Oct 21, 2030 Msd Sub Merck
Isentress US8771733 Pharmaceutical composition containing an anti-nucleating agent Jun 02, 2030 Msd Sub Merck
Isentress Hd US8771733 Pharmaceutical composition containing an anti-nucleating agent Jun 02, 2030 Msd Sub Merck
Isentress US7754731

(Pediatric)

Potassium salt of an HIV integrase inhibitor Sep 11, 2029 Msd Sub Merck
Isentress Hd US7754731

(Pediatric)

Potassium salt of an HIV integrase inhibitor Sep 11, 2029 Msd Sub Merck
Isentress US7754731 Potassium salt of an HIV integrase inhibitor Mar 11, 2029 Msd Sub Merck
Isentress Hd US7754731 Potassium salt of an HIV integrase inhibitor Mar 11, 2029 Msd Sub Merck
Isentress US8852632 Pharmaceutical formulation containing a release rate controlling composition Jan 28, 2028 Msd Sub Merck
Isentress US7169780

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr 03, 2024

(Expired)

Msd Sub Merck
Isentress Hd US7169780

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr 03, 2024

(Expired)

Msd Sub Merck
Isentress US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct 03, 2023

(Expired)

Msd Sub Merck
Isentress US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct 03, 2023

(Expired)

Msd Sub Merck
Isentress Hd US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct 03, 2023

(Expired)

Msd Sub Merck
Isentress US7217713

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr 21, 2023

(Expired)

Msd Sub Merck
Isentress US7435734

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr 21, 2023

(Expired)

Msd Sub Merck
Isentress Hd US7217713

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr 21, 2023

(Expired)

Msd Sub Merck
Isentress Hd US7435734

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr 21, 2023

(Expired)

Msd Sub Merck
Isentress US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct 21, 2022

(Expired)

Msd Sub Merck
Isentress US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct 21, 2022

(Expired)

Msd Sub Merck
Isentress Hd US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct 21, 2022

(Expired)

Msd Sub Merck
Isentress Hd US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct 21, 2022

(Expired)

Msd Sub Merck



Raltegravir Potassium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List